Three complete responses in metastatic pancreatic cancer would be unremarkable in almost any other tumor type. In this disease, where published data across chemotherapy, checkpoint inhibitor, and RAS inhibitor regimens put confirmed complete response rates at roughly 0% to 8%, and where durable remissions are genuinely rare, three consecutive complete responses in the same small cohort carry disproportionate weight. That is the signal Elicio Therapeutics is now building a clinical program around.
The observations come from patients who enrolled in the Phase 2 AMPLIFY-7P trial of ELI-002 7P, a subcutaneous AMP-modified peptide vaccine targeting mutant KRAS. All three progressed on ELI-002 7P and subsequent gemcitabine/nab-paclitaxel chemotherapy before receiving nivolumab-based therapy. What followed was confirmed complete radiographic and metabolic response in every case, with concurrent normalization of CA19-9. Two patients sustained those responses for at least eight months; one remains in complete response beyond 13 months. Critically, all three were microsatellite stable and mismatch repair proficient, a population that historically responds to anti-PD-1 therapy at rates around 4% in pancreatic cancer, and where prior nivolumab monotherapy studies have returned no objective responses at all in this setting. The mechanistic read Elicio is advancing is that ELI-002 7P-primed mKRAS-specific T cells, which persisted in all three patients at the time of checkpoint inhibitor exposure, resensitized tumors that would otherwise have been immunologically cold.
The clinical design question this raises is whether the effect can be reproduced prospectively. Elicio intends to initiate a Phase 1 study, subject to funding, evaluating ELI-002 7P combined with gemcitabine/nab-paclitaxel and an anti-PD-1 inhibitor in treatment-naive first-line metastatic mKRAS PDAC. The company’s rationale for starting in the metastatic setting rather than adjuvant is straightforward: radiographic response can be assessed within months, producing a faster efficacy read than recurrence-free survival endpoints require. With KRAS mutations present in roughly 84.5% of metastatic PDAC cases, the addressable population for a validated mKRAS-targeting vaccine is not narrow. If the Phase 1 combination study generates a meaningful complete response rate, that data would directly inform the design of Elicio’s planned Phase 3 adjuvant trial, compressing the information gap between mechanistic hypothesis and late-stage program design.
The single number to track as this Phase 1 takes shape is the confirmed complete response rate in its MSS/MMR-proficient patients specifically. If the 3-for-3 pattern reflects genuine immune priming rather than selection noise, that subgroup rate will be the clearest evidence that ELI-002 7P is doing something checkpoint inhibitors alone cannot.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
